Short-term tranexamic acid treatment reduces in-hospital mortality in aneurysmal sub-arachnoid hemorrhage: A multicenter comparison study

• DOI: 10.1371/journal.pone.0211868
• Publication Date: 2019-02-07T20:31:56Z
• Authors: R. Post; M. R. Germans; H. D. Boogaarts; B. Ferreira Dias ...; R. Van den Berg; B. A. Coert; W. P. Vandertop; D. Verbaan
• Keywords: Antifibrinolytic

Background Recurrent bleeding is one of the major causes morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage (aSAH). Antifibrinolytic therapy known to reduce recurrent bleeding, however, its beneficial effect on outcome remains unclear. The treatment tranexamic acid (TXA) until aneurysm clinical evaluated. Methods Patients an aSAH from two high-volume tertiary referral centers Netherlands, Academic Medical Center (AMC) Radboud University (RUMC), between January 2012 December 2015 were included. classified into groups; standard or TXA treatment. Demographic characteristics, in-hospital complications compared groups. Multivariate logistic regression was used adjust for influence center baseline differences. Results Standard given 509 patients, 119 received additional before occlusion. treated did not experience less adjusted unadjusted (adjusted odds ratio [aOR] 0.80, 95% confidence interval [95% CI]: 0.37–1.73). In-hospital mortality, significantly lower group than care OR 0.42, CI: 0.20–0.85). Poor (mRS 4–6) assessed after six months different groups (aOR 1.05, 0.64–1.74). Conclusions Pooled data show improved patients. However, associated a decrease mortality.